Siglec-8: 천식의 호산구성 염증과기도개형에 대한 새로운 치료적 접근
Siglec-8: Novel Therapeutic Approach for EosinophilicInflammation and Airway Remodeling
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Eosinophil is an important therapeutic target in the management of asthma due to their important role in airway inflammation, induction of airway hyperresponsiveness and their recently described role in airway remodeling. One such strategy targeting eosinophils is to target receptors expressed by eosinophils that might mediate the resolution of eosinophilic inflammation. One candidate receptor expressed by eosinophils is Siglec-8. Siglec-8 belongs to the CD33-related Siglec (CD33rSiglec) family, which are a subclass of Siglecs defined by their mutual sequence similarity (share about 50-80% sequence similarity), and clustered gene localization (chromosome 19q in humans). The cytoplasmic domain of the Siglec-8 contains immunoreceptor tyrosine-based inhibition motifs (ITIMs), suggesting that this molecule possesses inhibitory functions. In vitro studies demonstrated that cross-linking Siglec-8 receptors on eosinophils induced an apoptotic signal through the sequential production of reactive oxygen species (ROS), followed by induction of mitochondrial injury and caspase cleavage. In vivo studies using Siglec-F (functional paralog of Siglec-8) deficient mice demonstrated that Siglec-F deficient mice challenged with inhaled allergen significantly enhanced levels of eosinophilic airway inflammation as well as delayed resolution of eosinophilic inflammation. Administration of an anti-Siglec-F antibody significantly reduced levels of allergen induced eosinophilic airway inflammation and features of airway remodeling by reducing the production and increasing the clearance of eosinophils in murine model of asthma. Although further studies are needed to elucidate the precise role of Siglec- 8, the results of these studies suggest that targeting of Siglec-8 may be a novel therapeutic approach for asthma and other allergic disease.
Abstract
Eosinophil is an important therapeutic target in the management of asthma due to their important role in airway inflammation, induction of airway hyperresponsiveness and their recently described role in airway remodeling. One such strategy targeting eosinophils is to target receptors expressed by eosinophils that might mediate the resolution of eosinophilic inflammation. One candidate receptor expressed by eosinophils is Siglec-8. Siglec-8 belongs to the CD33-related Siglec (CD33rSiglec) family, which are a subclass of Siglecs defined by their mutual sequence similarity (share about 50-80% sequence similarity), and clustered gene localization (chromosome 19q in humans). The cytoplasmic domain of the Siglec-8 contains immunoreceptor tyrosine-based inhibition motifs (ITIMs), suggesting that this molecule possesses inhibitory functions. In vitro studies demonstrated that cross-linking Siglec-8 receptors on eosinophils induced an apoptotic signal through the sequential production of reactive oxygen species (ROS), followed by induction of mitochondrial injury and caspase cleavage. In vivo studies using Siglec-F (functional paralog of Siglec-8) deficient mice demonstrated that Siglec-F deficient mice challenged with inhaled allergen significantly enhanced levels of eosinophilic airway inflammation as well as delayed resolution of eosinophilic inflammation. Administration of an anti-Siglec-F antibody significantly reduced levels of allergen induced eosinophilic airway inflammation and features of airway remodeling by reducing the production and increasing the clearance of eosinophils in murine model of asthma. Although further studies are needed to elucidate the precise role of Siglec- 8, the results of these studies suggest that targeting of Siglec-8 may be a novel therapeutic approach for asthma and other allergic disease.
참고문헌 (25)
- Jacoby DB, "Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor", J Clin Invest, 91(4), pp.1314~1318 (1993)
- Bandeira-Melo C, "The cellular biology of eosinophil eicosanoid formation and function", J Allergy Clin Immunol, 109(3), pp.393~400 (2002)
- Rothenberg ME, "The eosinophil", Annu Rev Immunol, 24, pp.147~174 (2006)
- Flood-Page P, "Anti- IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics", J Clin Invest, 112(7), pp.1029~1036 (2003)
- Cho JY, "Inhibition of airway remodeling in IL-5-deficient mice", J Clin Invest, 113(4), pp.551~560 (2004)
- Leckie MJ, "Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response", The Lancet, 356(9248), pp.2144~2148
- Flood-Page PT, "Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway", Am. J. Respir. Crit. Care Med, 167(2), pp.199~204 (2003)
- Fulkerson PC, "A central regulatory role for eosinophils and the eotaxin", CCR3 axis in chronic experimental allergic airway inflammation, 2006, 16418~16423
- Wegmann M, "Effects of a low- molecular-weight CCR-3 antagonist on chronic experimental asthma", Am J Respir Cell Mol Biol, 36(1), pp.61~67 (2007)
- Crocker PR, "Siglecs: Sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling", Curr Opin Struct Biol, 12(5), pp.609~615 (2002)
- Crocker PR, "Siglecs and their roles in the immune system", Nat Rev Immunol, 7(4), pp.255~266 (2007)
- Balaian L, "The inhibitory effect of anti-CD33 monoclonal antibodies on aml cell growth correlates with syk and", or zap -70 expression, 2003, pp.31(5), 363~371
- von Gunten S, "Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment", Blood, 106(4), pp.1423~1431 (2005)
- Avril T, "The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by siglecs-7 and -9, CD33-related siglecs expressed on human monocytes and nk cells", J Immunol, 173(11), pp.6841~6849 (2004)
- Paul SP, "Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases shp-1 and shp- 2", Blood, 96(2), pp.483~490 (2000)
- Avril T, "Negative regulation of leucocyte functions by CD33-related siglecs", Biochem Soc Trans, 34(6), pp.1024~1027 (2006)
- Nutku E, "Ligation of siglec-8: A selective mechanism for induction of human eosinophil apoptosis", Blood, 101(12), pp.5014~5020 (2003)
- Nutku E, "Mechanism of siglec-8-induced human eosinophil apoptosis: Role of caspases and mitochondrial injury", Biochem Biophys Res Commun, 336(3), pp.918~924 (2005)
- Nutku-Bilir E, "Interleukin-5 priming of human eosinophils alters siglec-8 mediated apoptosis pathways", Am J Respir Cell Mol Biol, 38(1), pp.121~124 (2008)
- Tateno H, "Mouse siglec-F and human siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo- sialyl lewis X as a preferred glycan ligand", Glycobiology, 15(11), pp.1125~1135 (2005)
- Zhang M, "Defining the in vivo function of siglec-F, a CD33-related siglec expressed on mouse eosinophils", Blood, 109(10), pp.4280~4287 (2007)
- Mingari MC, "P75", AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells, 2001, pp.181, 260~268
- Vitale C, "Engagement of p75", AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells, 1999, pp.통권 : 96, 15091~15096
- Munitz A, "The inhibitory receptor IRp60 (CD300a) suppresses the effects of IL-5, GM-CSF, and eotaxin on human peripheral blood eosinophils", Blood, 107(5), pp.1996~2003 (2006)
- RI-dependent mediator release and calcium flux from human mast cells by sialic acid- binding immunoglobulin-like lectin 8 engagement, "Journal of Allergy and Clinical Immunology", 2008, 499~505